iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: http://pubmed.ncbi.nlm.nih.gov/27401882/
Sleep and Quality of Life Under Prolonged Release Oxycodone/Naloxone for Severe Restless Legs Syndrome: An Analysis of Secondary Efficacy Variables of a Double-Blind, Randomized, Placebo-Controlled Study with an Open-Label Extension - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2016 Aug;30(8):749-60.
doi: 10.1007/s40263-016-0372-1.

Sleep and Quality of Life Under Prolonged Release Oxycodone/Naloxone for Severe Restless Legs Syndrome: An Analysis of Secondary Efficacy Variables of a Double-Blind, Randomized, Placebo-Controlled Study with an Open-Label Extension

Wolfgang H Oertel  1 , Yngve Hallström  2 , Gerda M Saletu-Zyhlarz  3 , Michael Hopp  4 , Björn Bosse  4 , Claudia Trenkwalder  5   6 ; RELOXYN Study Group
Collaborators, Affiliations
Randomized Controlled Trial

Sleep and Quality of Life Under Prolonged Release Oxycodone/Naloxone for Severe Restless Legs Syndrome: An Analysis of Secondary Efficacy Variables of a Double-Blind, Randomized, Placebo-Controlled Study with an Open-Label Extension

Wolfgang H Oertel et al. CNS Drugs. 2016 Aug.

Abstract

Objective: The aim was to assess the effects of prolonged release oxycodone/naloxone (OXN PR) on sleep and quality of life (QoL) in patients with severe restless legs syndrome (RLS) refractory to first-line dopaminergic RLS treatment.

Methods: Sleep and QoL data from a 12-week, randomized, double-blind, placebo-controlled study with subsequent 40-week, open-label extension were analyzed. Instruments included the Medical Outcomes Study (MOS) sleep scale, RLS-6 rating scale, and RLS-QoL questionnaire.

Results: The full analysis population included 132 OXN PR and 144 placebo patients. After 12 treatment weeks, improvements in the MOS domains 'sleep disturbance' [-18.6; 95 % confidence interval (CI) -24.4 to -12.9; p < 0.0001], 'sleep adequacy' (14.9; 95 % CI 7.9-21.9; p < 0.0001), and 'sleep quantity' (0.77 h; 95 % CI 0.43-1.11; p < 0.0001) were significantly greater under OXN PR than under placebo. OXN PR also reduced symptom severity (when falling asleep and during the night) and daytime tiredness, and increased sleep satisfaction to a significantly greater extent than placebo (all p < 0.001; RLS-6). QoL improved in both treatment arms, with a significant difference of -9.02 (95 % CI -12.85 to -5.19; p < 0.001) in the mean sum score in favor of OXN PR. All sleep and QoL aspects also improved under 40 weeks of open-label OXN PR treatment.

Conclusions: OXN PR improved RLS symptom severity and sleep quantity and adequacy, resulting in greater sleep satisfaction, less daytime tiredness, and improved QoL. In appropriate patients, OXN PR should be considered as an alternative treatment option for severe RLS that cannot be controlled by first-line dopaminergic medications.

Trial registration: ClinicalTrials.gov (NCT01112644) and EudraCT (2009-011107-23).

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Study design. OXN PR prolonged release oxycodone/naloxone, V visit
Fig. 2
Fig. 2
Study profile. Reprinted from The Lancet Neurology [12], Trenkwalder et al., Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension. Pages 1141–50, copyright (2013), with permission from Elsevier
Fig. 3
Fig. 3
Mean change (SE) from baseline to end of 12-week, double-blind study phase in Medical Outcomes Study sleep scale domains (full analysis set, OXN PR n = 132, placebo n = 144). *p < 0.0001 compared with placebo. Item scores were converted to a 0–100 scale, except for sleep quantity (h), according to Spritzer and Hays [17]. Decreases in sleep disturbance and daytime somnolence and increases in sleep adequacy and sleep quantity indicate improvements. OXN PR prolonged release oxycodone/naloxone, SE standard error
Fig. 4
Fig. 4
Mean changes (+SE) in QoL (sum score) during the study. Full analysis set for the double-blind phase: OXN PR n = 132, placebo n = 144, LOCF data; baseline extension: n = 197; end of extension: n = 190. LOCF last observation carried forward, OXN PR prolonged release oxycodone/naloxone, QoL quality of life, SE standard error
Fig. 5
Fig. 5
Mean changes (+SE) in RLS-QoL dimensions at start of study and end of 12-week, double-blind phase. Full analysis set (LOCF data); *p < 0.001 compared with placebo. Dimensions: effects of RLS symptoms (items 1–4: impairment of sleep, general performance, mental health, and social activities); disturbed sleep and its effects (item 5 and 6: impairment of daily activities due to lack of sleep, impairment of well-being due to daytime tiredness); effects of other features (item 7 and 8: medication side effects, arm or leg pain); coping with RLS symptoms (items 9–11: strain of using coping strategies, avoidance of certain activities/situations, strain of lifestyle changes); and overall quality of life summary question (item 12). LOCF last observation carried forward, QoL quality of life, RLS restless legs syndrome, SE standard error
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Allen RP, Picchietti DL, García-Borreguero D, et al. Restless legs syndrome/Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria—history, rationale, description, and significance. Sleep Med. 2014;15:860–873. doi: 10.1016/j.sleep.2014.03.025. - DOI - PubMed
    1. Allen RP, Picchietti D, Hening WA, et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med. 2003;4:101–109. doi: 10.1016/S1389-9457(03)00010-8. - DOI - PubMed
    1. Tzonova D, Larrosa O, Calvo E, et al. Breakthrough symptoms during the daytime in patients with restless legs syndrome (Willis-Ekbom disease) Sleep Med. 2012;13:151–155. doi: 10.1016/j.sleep.2011.09.015. - DOI - PubMed
    1. Zhang C, Li Y, Malhotra A, Ning Y, Gao X. Restless legs syndrome status as a predictor for lower physical function. Neurology. 2014;82:1212–1218. doi: 10.1212/WNL.0000000000000284. - DOI - PMC - PubMed
    1. Hanewinckel R, Makimovic A, Verlinden VJA, et al. The impact of restless legs syndrome on physical functioning in a community-dwelling population of middle-aged and elderly people. Sleep Med. 2015;16:399–405. doi: 10.1016/j.sleep.2014.11.013. - DOI - PubMed

Publication types

Associated data